A randomized clinical trial of Italian cancer patients in 16 hospital wards showed those treated using the end-of-life Liverpool Care Pathway did not have better survival times or significantly improved care compared with patients who received standard care. Use of the LCP is being phased out in the U.K., and study co-author Irene Higginson said the data show it will be important for future programs to be "grounded in scientific evidence and tested in controlled trials before being rolled out across the board."

Related Summaries